Kiadis Pharma to present at upcoming conferences in November 2019
05 Novembre 2019 - 5:50PM
Kiadis Pharma to present at upcoming conferences in November 2019
Amsterdam, The Netherlands, November 5, 2019
– Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces that the Kiadis
management team will present and will host meetings at the
following conferences in November 2019.
FT Global Pharmaceuticals and Biotechnology
SummitNovember 12, 2019, London, UKArthur Lahr, Chief Executive
Officer, will participate in a panel discussion related to
‘Rewarding Innovation: What is the Regulation we Need?’ held on
November 12th at 11:35am GMT.There is no live webcast
available.
Solebury Trout KOL DayNovember 15, 2019, New York,
USManagement will present on November 15th at 9:30am EST
Arthur Lahr, Chief Executive Officer, will begin with a brief
corporate overview which will be followed by a presentation from
Dean Lee, MD, PhD – Hematology and Oncology at Nationwide
Children’s Hospital and Director of the Cellular Therapy and Cancer
Immunology Program at Nationwide Children's Hospital, The Ohio
State U Comprehensive Cancer Center.A live webcast of the
presentation will be available here:
https://services.choruscall.com/links/kds191115.html
Stifel 2019 Healthcare ConferenceNovember 19, 2019, New
York, USManagement will present on November 19th at 4:10pm EST A
live webcast of the presentation will be available here:
http://wsw.com/webcast/stifel18/kds/
Jefferies 2019 London Healthcare ConferenceNovember 20,
2019, London, UKManagement will present on November 20th at 3:20pm
GMTA live webcast of the presentation will be available here:
http://wsw.com/webcast/jeff123/kds/
An archived replay of the webcasts will be available on the
Company's website for approximately 90 days following the
presentation.
Kiadis Contacts:
Kiadis
Pharma: Maryann Cimino, Manager, Corporate AffairsTel: +1 (617)
710-7305m.cimino@kiadis.com |
Optimum
Strategic Communications:Mary Clark, Supriya Mathur, Hollie
VileTel: +44 203 950 9144David Brilleslijper (Amsterdam)Tel: +31
610 942 514kiadis@optimumcomms.com |
About Kiadis
Founded in 1997, Kiadis Pharma, is a fully
integrated biopharmaceutical company committed to developing
innovative therapies for patients with late-stage blood cancers.
With headquarters in Amsterdam, the Netherlands, and offices and
activities in the US and across Europe, Kiadis Pharma is
reimagining medicine by leveraging the natural strengths of
humanity and our collective immune system to source the best cells
for life.
Kiadis Pharma is listed on the regulated market
of Euronext Amsterdam and Euronext Brussels since July 2, 2015,
under the symbol KDS. Learn more at kiadis.com.
Forward Looking StatementsCertain
statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis Pharma’s or, as appropriate,
Kiadis Pharma’s directors’ current expectations and projections
about future events. By their nature, forward-looking statements
involve a number of risks, uncertainties and assumptions that could
cause actual results or events to differ materially from those
expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, regulation, competition and technology, can
cause actual events, performance or results to differ significantly
from any anticipated development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in
events, conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.